Meta-Analysis of Combined Therapy with Angiotensin Receptor Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure by Kuenzli, Andrea et al.
Meta-Analysis of Combined Therapy with Angiotensin
Receptor Antagonists versus ACE Inhibitors Alone in
Patients with Heart Failure
Andrea Kuenzli
1, Heiner C. Bucher
1, Inder Anand
2, Gregory Arutiunov
3, Leo C. Kum
4, Robert McKelvie
5,
Rizwan Afzal
5, Michel White
6,7, Alain J. Nordmann
1*
1Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland, 2Cardiovascular Division, University of Minnesota Medical School,
Veterans Affairs Medical Center, Minneapolis, Minnesota, United States of America, 3Russian State Medical University, Moscow, Russian Federation, 4Division of
Cardiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People’s Republic of China, 5Population Health
Research Institute, Hamilton Health Sciences - General Site and McMaster University, Hamilton, Ontario, Canada, 6Research Center, Montreal Heart Institute, Montre ´al,
Quebec, Canada, 7Universite ´ de Montre ´al, Montre ´al, Quebec, Canada
Abstract
Background: There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to
angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart
failure.
Methodology/Principal Findings: Two independent reviewers searched and abstracted randomized controlled trials of
ARBs and ACE inhibitors compared to ACE inhibitor therapy alone in patients with heart failure reporting mortality and
hospitalizations having a follow-up of at least 6 months identified by a systematic literature search. Eight trials including a
total of 18,061 patients fulfilled our inclusion criteria. There was no difference between patients treated with combination
therapy and ACE inhibitor therapy alone for overall mortality, hospitalization for any reason, fatal or nonfatal MI.
Combination therapy was, however, associated with fewer hospital admissions for heart failure (RR 0.81, 95%CI 0.72–0.91),
although there was significant heterogeneity across trials (p-value for heterogeneity=0.04; I
2=57% [95%CI 0–83%]).
Patients treated with combination therapy had a higher risk of worsening renal function and symptomatic hypotension, and
their trial medications were more often permanently discontinued. Lack of individual patient data precluded the analysis of
time-to-event data and identification of subgroups which potentially benefit more from combination therapy such as
younger patients with preserved renal function and thus at lower risk to experience worsening renal function or
hyperkalemia.
Conclusions/Significance: Combination therapy with ARBs and ACE inhibitors reduces admissions for heart failure in
patients with congestive heart failure when compared to ACE inhibitor therapy alone, but does not reduce overall mortality
or all-cause hospitalization and is associated with more adverse events. Thus, based on current evidence, combination
therapy with ARBs and ACE inhibitors may be reserved for patients who remain symptomatic on therapy with ACE inhibitors
under strict monitoring for any signs of worsening renal function and/or symptomatic hypotension.
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Introduction
Congestive heart failure is a major and growing public health
problem in the United States. Approximately 5 million patients
suffer from congestive heart failure, and over half a million
patients are newly diagnosed with congestive heart failure each
year [1]. The disorder is the primary reason for 12 to 15 million
office visits and 6.5 million hospital days each year [1]. The
estimated direct and indirect cost of congestive heart failure in the
United States for 2006 was $29.6 billion [2].
Several therapeutic approaches in congestive heart failure
management have led to an important reduction of cardiovascular
morbidity and mortality like the blockade of the renin-angiotensin
system by angiotensin-converting enzyme (ACE) inhibitors [3–7].
However, ACE inhibitors are unable to completely block the
persistent activation of the renin-angiotensin system [8,9] due to the
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e9946existence of ACE-independent pathways (e.g., chymase, cathepsin,
and kallikrein) converting angiotensin I to angiotensin II.
Therefore, the combination of ACE inhibitors and angiotensin
II receptor blockers (ARBs) has been propagated for more
complete blockade of the renin-angiotensin system [10,11]. The
combination of ACE inhibitors and ARBs decreases more
effectively the plasma concentrations of aldosterone and brain
natriuretic peptide than either ACE inhibitors or ARB alone
[12,13]. The addition of ARB to background therapy with ACE
inhibitors has an additional attenuating effect on LV remodeling
[14], and thus offers the potential to reduce cardiovascular
morbidity and mortality in patients with congestive heart failure.
However, combining ACE inhibitors and ARBs may cause
important adverse effects. In 2 recently published meta-analyses the
combination of ARBs and ACE inhibitors was associated with more
adverse effects ascompared toACEinhibitortherapy alone[15,16].
However, both meta-analyses focussed on adverse effects associated
with combination therapy and did not address outcomes such as
readmission for heart failure or mortality where combination
therapy may offer a benefit over ACE inhibitor therapy alone. One
earlier published meta-analysis indicated a benefit from combina-
tion therapy compared to ACE-inhibitor alone on readmission rates
for heart failure [17], but failed to report overall readmission rates
which are of particular interest based on the observed increase in
adverse effects observed in the 2 meta-analyses mentioned above.
Another meta-analysis limited its analysis to overall mortality and a
combined outcome of overall mortality and morbidity [18]. There
wasnodifferenceinoverall mortality. Forsomereasons, authors did
not provide information about which individual outcomes they
summarized under the term ‘‘morbidity’’. Thus, in patients with
congestive heart failure it remains unclear whether any potential
benefit of combination therapy on outcomes may be outweighed by
an increase in adverse events. In order to resolve this issue, we
conducted a comprehensive meta-analysis to investigate the effectof
adding ARBs to ACE inhibitor therapy alone in terms of clinically
relevant beneficial and adverse patient important outcomes
including hospital readmissions for any reason.
Methods
Eligibility criteria for this meta-analysis were randomized
controlled trials comparing combined ARB and ACE inhibitor
therapy to ACE inhibitor therapy alone in patients with left
ventricular dysfunction or congestive heart failure, with a minimal
6 months follow-up that reported mortality and hospitalization
outcomes. For eligible trials we required a background therapy
with ACE inhibitor therapy in at least 90% of patients.
Data sources and search
The electronic databases MEDLINE, EMBASE, PASCAL (all
from their inception to December 2009) and the Cochrane
Central Register of Controlled Trials were searched for the terms
‘‘Angiotensin-Converting Enzyme Inhibitors’’, ‘‘Angiotensin II
Receptor Blockers’’ as text words and ‘‘Angiotensin-Converting
Enzyme Inhibitors’’, ‘‘Angiotensin II Type 1 Receptor Blockers’’,
‘‘losartan’’, ‘‘valsartan’’, ‘‘candesartan’’, ‘‘irbesartan’’, ‘‘eprosar-
tan’’, ‘‘olmesartan’’, ‘‘telmisartan’’, and ‘‘receptors, angiotensin/
antagonists and inhibitors’’ as Medical Subject Headings. We
restricted the search to articles indexed as clinical trial (publication
type) or those that included the words random or placebo in their
titles or abstracts. No language restrictions were imposed. We also
searched reference lists of identified articles, clinical trial register of
ongoing or planned trials, recently published editorials and reviews
on the topic for further eligible trials. Authors of included primary
trials were asked to contribute additional data relevant for the
purpose of this analysis.
Selection and quality assessment
Two authors independently assessed trial eligibility and quality.
We assessed the quality of trials according to concealment of
treatment allocation, blinding of patients, caregivers, or clinical
outcome assessors, full description of losses to follow-up and
withdrawals and the proportion of patients with complete clinical
follow-up [19]. We considered treatment allocation to be
concealed if a central independent randomization facility, the
use of numbered sealed opaque envelopes, or a central pharmacy
which prepared and distributed numbered containers were
mentioned in the report.
Endpoints and data extraction
Two authors (AK, AN) independently extracted in duplicate all
trial data and the additional data provided by the original
investigators. Endpoints and adverse effects were considered
irrespective of their putative relation to the treatment. We assessed
the following clinical endpoints at the latest time of follow-up
available: Total mortality, hospitalizations for heart failure
(defined as number of distinct patients with rehospitalization for
heart failure), hospitalizations for any reason (defined as number of
distinct patients with rehospitalization for any reason), nonfatal
myocardial infarction (MI), fatal MI, revascularisation procedures
(PCI, CABG), fatal and non-fatal strokes, and quality of life.
We also gathered information about the frequency of the
following adverse effects as defined by individual trials’ definitions:
Worsening renal function, symptomatic hypotension, hyperkale-
mia, cough, rash, angioedema and permanent discontinuation of
study medication.
Statistical analysis
We pooled treatment effects and calculated risk ratios for all
clinical endpoints in the treatment and control groups by using a
random effects model [20]. The presence of publication bias was
investigated by means of funnel plots [21]. We tested for
heterogeneity with the Cochrane Q test and measured inconsis-
tency (I
2; the percentage of total variance across studies that is due
to heterogeneity rather than chance) of treatment effects across all
clinical endpoints and averse effects [22,23]. We conducted
sensitivity analyses to examine treatment effects according to:
quality components of included trials (concealed treatment
allocation, blinding of patients and caregivers, blinded outcome
assessment); trials including patients with acute MI versus trials
including patients without acute MI; trials with a clear
specification to achieve target doses and where $80% of patients
in the combination group reached these target dose of the
prescribed ARB versus trials where , than 80% of patients
reached the target dose of the prescribed ARB; trials where $50%
versus trials where ,50% of included patients received beta-
adrenergic antagonists; limitation of analysis to trials including
more than 100 patients, and trials including patients with different
causes (ischemic versus non-ischemic) and severity of congestive
heart failure (NYHA I and II versus NYHA III and IV). We used
Stata 9.2 (StataCorp, College Station/Texas) for data analysis.
Results
Eight trials including a total of 18 061 patients fulfilled our
inclusioncriteria[Figure1-selectionprocessofincludedtrials].The
relatively small number of trials precluded a sensitive exploration of
publication bias, although the plot of standardized effect against
ARB’s in Heart Failure
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Characteristics of included trials are summarized in Table 1.
Follow-up periods of individual trials ranged from 6 to 41
months. Mean age of enrolled patients ranged from 54 to 69 years.
The majority of the included patients were men (range from 48 to
94%). The vast majority of included patients had congestive heart
failure NYHA class II–III with mean left ventricular ejection
fraction between 25% and 35%. Most included patients (82%) had
ischemic heart failure, followed by idiopathic (13%) and
hypertensive heart failure (3%). Diabetes was present in 25%,
hypertension in 40% of patients. Baseline characteristics of
included patients are summarized in Table 2.
There were two post-myocardial infarction (MI) trials. In
VALIANT [24] patients were included if the ejection fraction was
#35% within 12 hours to ten days after an acute MI and
accompanied by clinical or radiological signs of congestive heart
failure. Another trial [25] included hemodynamically stable
patients with an ejection fraction #35% from 72 to 96 hours
after an acute MI.
In the RESOLVD trial [26], patients were first randomly
assigned to enalapril, candesartan or their combination, and in a
second step after five months then randomly allocated to receive
metoprolol or placebo in addition.
Three trials required patients to be on ACE inhibitor therapy
for at least one [27] or three months [28,29]. Two trials used a two
to four week run-in-phase [26,30].
Only four trials aimed at reaching the maximum recommended
dose of the ARB [27–30] [Table 1]. The percentage of patients
reaching individual trials’ target dose of ARBs ranged from 47%
[27] to 100% [31]. As for standard therapy, four trials aimed at
reaching maximum recommended target dose of individual ACE
inhibitor therapy [24,26,28,31]. The percentage of patients
reaching the maximum recommended dose of ACE inhibitor
therapy ranged from 53% [31] to 94% [28]. In contrast, the other
four trials [25,27,28,30] did not report recommended fixed target
doses of ACE inhibitor therapy, although in one trial clinicians
were advised to target the doses of ACE inhibitors known to
reduce morbidity and mortality in patients with congestive heart
failure [27]. The type and dose of ACE inhibitor therapy used in
either treatment groups were comparable in all but one trial [31],
where the average dose of the ACE inhibitors used was lower in
the standard therapy group. In one trial dosage of ACE inhibitors
was not reported [29].
Concomitant therapy varied among the different trials
[Table 3]. With the exception of one trial [25], at least half of
the patients were taking diuretics and digoxin. The use of beta-
adrenergic antagonists in individual trials varied widely from 6%
[31] up to 95% [28] of patients. Only one trial [29] reported on
the use of implantable cardiac defibrillators at the time of study
enrolment (4% of included patients). Outcomes of individual trials
are summarized in Table 4.
Quality of the trials
Five trials reported concealed treatment allocation
[24,25,27,29,30]. All but two trials [25,29] used a double blind
design. Blinded outcome assessment was reported in three trials
[24,27,29] [Table 1]. Full description of losses to follow-up and
withdrawals was reported in all but 2 trials [28,30]. All trials had a
loss to follow-up ,10%. The 2 reviewers were in full agreement
when rating the quality criteria assessed.
Overall Mortality
There was no difference in overall mortality between patients
treated with combination therapy compared to ACE inhibitor
therapy alone (RR 0.97, 95%CI 0.92–1.03, p-value for heteroge-
neity=0.49; I
2=0% [95%CI 0–68%]) [Figure 2 - mortality and
cardiovascular outcomes in randomized controlled trials compar-
ing angiotensin receptor antagonists and ACE inhibitors versus
ACE inhibitors alone in patients with heart failure].
Cardiovascular Endpoints and Quality of Life
Data on hospital admission for congestive heart failure were
available from all but 2 small trials [28,31]. There were fewer
patients with combination therapy compared to ACE inhibitor
therapy with hospital admissions due to congestive heart failure
(RR 0.81, 95%CI 0.72–0.91; p-value for heterogeneity=0.04;
I
2=57% [95%CI 0–83%]), but there was no difference between
groups for hospitalization for any reason (RR 0.92, 95% CI 0.82–
1.05; p-value for heterogeneity ,0.001, I
2=91% [95%CI 81–
95%]).
There was no difference between patients treated with
combination therapy and ACE inhibitor therapy alone for the
relative risks of fatal (RR 0.97, 95%CI 0.76–1.22, p-value for
heterogeneity=0.97; I
2=0% [95%CI 0–71%] and non-fatal MI
(RR 0.91, 95%CI 0.78–1.07, p-value for heterogeneity=0.31;
I
2=0% [95%CI 0–60%]). There was insufficient data for the
endpoints revascularization procedures and strokes.
Five trials [24,26,27,29,30] reported quality of life data. Due to
different quality of life scores used, it was not possible to pool the
results. Two trials found a significant difference in favour of the
Figure 1. Selection process of included trials. ACE-I angiotensin-
converting enzyme inhibitor, ARB angiotensin II receptor antagonist,
RCT randomized controlled trial.
doi:10.1371/journal.pone.0009946.g001
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PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e9946combination group using the Minnesota Living with Heart Failure
Questionnaire [29,30]. In the other three trials [24,32,33] there
was no difference between the quality of life of patients
randomized to combination or ACE inhibitor therapy alone.
One of these trials used the McMaster overall treatment
evaluation [32], the other the EuroQol-5D preference and visual
analogue scale score to measure quality of life [33]. One trial did
not report how quality of life was measured [26].
Adverse Effects
The reporting on adverse effects was inconsistent between trials
and details are provided in Figure 3 [adverse effects in randomized
Table 2. Baseline characteristics of patients enrolled in randomized controlled trials comparing combination therapy with
angiotensin II receptor antagonists and ACE inhibitor therapy versus ACE inhibitor therapy alone in patients with congestive heart
failure.
Trial Intervention
Total
n
Males
%
Age 6
SD
Diabetes
%
Hypertension
%
Smoking
%
Prior
MI %
Ischemic heart
disease %
EF
%
Hamroff et al. Combination therapy
ACE-I alone
16
17
31
65
62613
60610
31
47
56
76
25
29
-
-
31
29
2762
2662
RESOLVD Combination therapy
ACE-I alone
332
109
85
90
64611
63612
24
32
40
42
42
8
67
73
70
74
28611
276 9
Arutiunov GP et al. Combination therapy
ACE-I alone
35
79
60
67
6866
6267
11
21
60
59
49
70
86
69
14
31
33
32
Val-HeFT Combination therapy
ACE-I alone
2511
2499
80
80
62611
63611
26
25
-
-
-
-
-
-
58
57
2767
2867
CHARM Added Combination therapy
ACE-I alone
1276
1272
79
79
64611
64611
30
30
48
49
15
19
56
55
62
63
2868
2868
VALIANT Combination therapy
ACE-I alone
4885
4909
69.5
68.7
65612
65612
24
23
55
55
32
32
28
27
100
100
35610
35610
White M et al. Combination therapy
ACE-I alone
41
39
93
87
6369
6368
39
23
34
36
-
-
-
-
88
77
2667
2867
Kum L et. al. Combination therapy
ACE-I alone
25
25
76
68
66611
69610
32
40
20
16
-
-
36
44
68
64
30612
34613
ACE-I angiotensin-converting enzyme inhibitor, EF ejection fraction, MI myocardial infarction, n number, SD standard deviation, NYHA New York Heart Association.
doi:10.1371/journal.pone.0009946.t002
Table 3. Co-medication in randomized controlled trials comparing combination therapy with angiotensin II receptor antagonists
and angiotensin-converting enzyme inhibitor therapy versus ACE inhibitor therapy alone in patients with congestive heart failure.
Trial, year Intervention
b-Blocker
%
Spironolactone
%
Digoxin
%
Aspirin
%
Warfarin/
Marcoumar %
Lipid-lowering
drug %
Calcium
Antagonist %
Diuretic
%
Hamroff et al., 1999 Combination therapy 6 NA 94 38 19 NA 6 100
ACE-I alone 6 NA 100 29 35 NA 6 100
RESOLVD,1999 Combination therapy 13 NA 64 56 32 NA 15 84%
ACE-I alone 23 NA 79 47 30 NA 14 87
Arutiunov GP et al.,
2000
Combination
therapy
11 NA NA 20 NA NA 0 9
ACE-I alone 17 NA NA 20 NA NA 0 30
Val-HeFT, 2001 Combination therapy 44 NA 67 NA NA NA NA 86
ACE-I alone 36 NA 68 NA NA NA NA 85
CHARM Added, 2003 Combination therapy 55 17 58 51 38 41 10 90
ACE-I alone 56 17 59 52 38 41 11 90
VALIANT, 2003 Combination therapy 70 9 91 NA 34 NA 50
ACE-I alone 70 9 91 NA 34 NA 49
White M, et al., 2007 Combination therapy 95 40 61 NA NA 68 7 80
ACE-I alone 92 44 64 NA NA 87 8 82
Kum L et al., 2008 Combination therapy 64 0 12 68 0 60 NA 88
ACE-I alone 64 0 8 64 0 48 NA 84
ACE-I angiotensin-converting enzyme inhibitor, NA not available.
doi:10.1371/journal.pone.0009946.t003
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PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e9946controlled trials comparing angiotensin receptor antagonists and
ACE inhibitors versus ACE inhibitors alone in patients with heart
failure]. Two trials reported on the worsening of renal function
defined as a $50% increase of serum creatinine from baseline
[26,27]. One trial [24] defined worsening renal failure as one of
the following: death from renal failure, end-stage renal disease
requiring chronic dialysis or renal transplantation, or an increase
in serum creatinine concentration leading to temporary or
Figure 2. Mortality and cardiovascular outcomes in randomized controlled trials comparing angiotensin receptor antagonists and
ACE inhibitors versus ACE inhibitors alone in patients with heart failure.
doi:10.1371/journal.pone.0009946.g002
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PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e9946permanent discontinuation of study medication. In all other trials
worsening of renal function was not defined. No trial provided an
exact definition of symptomatic hypotension. Hyperkalemia was
defined as a serum potassium level $5.5mmol/l in two trials
[26,28], $6mmol/l in one trial [27], as significant hyperkalemia
requiring treatment in one trial [29], and leading to discontinu-
ation of study medication in another trial [24]. The definition of
hyperkalemia was not reported in 3 trials [25,30,31].
Patients treated with combination therapy had a higher risk of
worsening renal function than patients treated with ACE inhibitor
therapy alone (RR 1.91, 95%CI 1.40–2.60, p-value for heteroge-
neity=0.12; I
2=46% [95%CI 0–80%]), symptomatic hypoten-
sion (RR 1.57, 95%CI 1.44–1.71, p-value for heterogene-
ity=0.99; I
2=0%[95%CI 0–79%]) and an increased risk of
developing hyperkalemia (RR 1.95, 95%CI 0.85–4.48, p-value for
heterogeneity=0.007; I
2=75%[95%CI 31–91%]). Trial medica-
tions were more often permanently discontinued in patients
treated with combination therapy than in patients treated with
ACE inhibitor therapy alone (RR 1.21, 95%CI 1.07–1.37, p-value
for heterogeneity=0.14; I
2=38% [95%CI 0–74%]). There were
no differences in the occurrence of cough, angioedema or rash
between the two groups.
Sensitivity Analyses
There were no qualitative differences in summary estimates for
any outcomes of trials with and without concealed treatment
allocation, double-blind design or blinded outcome assessment.
Similarly, there were no qualitative changes in summary estimates
for all outcomes when repeating the analyses after exclusion of
those 2 trials that only included patients acute MIs [24,25]. In this
sensitivity analysis, however, there was no longer heterogeneity for
hospital admissions due to congestive heart failure (RR 0.81; 95%
CI 0.72–0.91, p-value for heterogeneity=0.28, I
2=23% [95%CI
0–88%]), but heterogeneity for the summary estimate of
hospitalization for any reason did persist (RR 0.92; 95% CI
0.75–1.14, p-value for heterogeneity ,0.001, I
2=90% [95%CI
78–96%]).
There were no qualitative differences in summary estimates for
any outcomes of trials that did respectively did not achieve ARB
target doses although for admission for congestive heart failure
heterogeneity for the summary estimates in trials achieving ARB
target doses was reduced (RR 0.80; 95% CI 0.73–0.87, p-value for
heterogeneity=0.427, I
2=0% [95%CI 0–90%]). In trials with
$50% versus ,50% of patients receiving beta-adrenergic
antagonists, no difference in summary estimates were found in
Figure 3. Adverse effects in randomized controlled trials comparing angiotensin receptor antagonists and ACE inhibitors versus
ACE inhibitors alone in patients with heart failure.
doi:10.1371/journal.pone.0009946.g003
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e9946any outcomes. There were no qualitative differences in summary
estimates for any outcomes when limiting the analyses to trials
including more than 100 patients. Lack of individual patient data
precluded us from conducting sensitivity analyses according to
different etiologies (ischemic versus non-ischemic) or severity of
heart failure (NYHA I and II versus NYHA III and IV).
Discussion
In this meta-analysis, combination therapy of an ARB and an
ACE inhibitor as compared to ACE inhibitor therapy alone did
not reduce patient important cardiovascular outcomes such as
overall mortality or non-fatal myocardial infarction in patients
with left ventricular dysfunction or congestive heart failure.
Combination therapy was associated with a reduction in patients’
hospital admission for heart failure, but the risk for hospitalization
for any reason was not affected. Combination therapy was
associated with increased side effects such as worsening of renal
function, hypotension and a tendency towards hyperkalemia in
those trials where information was available.
Our study is based on trials retrieved from an extensive
literature search to identify all relevant eligible trials comparing
combination of ARB plus ACE inhibitor therapy to ACE inhibitor
therapy alone in patients with congestive heart failure. In
comparison to earlier published meta-analyses [15–18], our
meta-analysis offers the advantage to simultaneously provide risk
estimates on all patient relevant outcomes including hospital
readmission rates for any reason which have not been reported in
any of the previous meta-analyses.
Although formal testing did not indicate any publication bias,
such bias cannot definitely be ruled out due to the small number of
trials included and the low power of any test to detect a publication
bias. Although only 3 of 8 included studies reported blinded
outcome assessment, the quality of the included trials was
generally good. In addition, the results of our analyses proved to
be robust across various sensitivity analyses. Our analysis has
several limitations. Only four trials aimed at reaching recom-
mended full dose ARB therapy in the combination group [27–30].
Furthermore, in only 4 trials [26,28,30,31] $80% of patients in
the combination group reached the individual trials’ target dose of
the recommended ARB. It could therefore be argued that our
results may underestimate the benefit of full dose combination
therapy. However, in sensitivity analyses there was no qualitative
difference in any of the outcomes analyzed when trials aiming at
reaching recommended full dose ARB therapy were compared to
trials where $80% of patients in the combination group reached
the target dose of the recommended ARB. Although our sensitivity
analysis may have lacked the power to demonstrate a difference in
outcomes, it seems unlikely that higher doses of ARBs would lead
to a greater benefit. In contrary, the fact that it proved difficult to
reach recommended target dose of ARBs in individual trials most
likely reflects the higher incidence of adverse effects associated
with combination therapy. Any increase in the dose of ARBs in
combination therapy may therefore lead to an even higher
incidence of adverse effects without further benefit. In addition,
only four trials [24,26,28,31] reported to have aimed at using a
fully recommended dose of an ACE inhibitor in the standard
therapy group. Thus, the results of our meta-analysis may
therefore rather over- than underestimate the beneficial effect of
combination therapy.
The use of concomitant therapy with beta-adrenergic antago-
nists, a class of drugs with proven efficacy in the treatment of heart
failure [34,35], varied widely across trials, but was far from
optimal. In only three trials [24,28,29] more than 50% of patients
were taking beta-adrenergic antagonists in addition to ACE
inhibitors and in only one small trial .90% were taking beta-
adrenergic antagonists [29]. There is therefore insufficient
evidence to answer the question whether the addition of ARBs
to standard therapy with ACE inhibitors and beta-adrenergic
antagonists offers any benefit in patients with heart failure.
In the absence of any benefit of combination therapy on
mortality, the found effect on hospitalization due to heart failure
may be of particular importance in view of the high costs
associated with recurrent hospitalizations. Data on the cost-
effectiveness of combination therapy compared to ACE inhibitor
therapy alone for the treatment of congestive heart failure are
scarce. In an analysis of resource utilization and costs in the
Charm-added trial [36], combination therapy led to either cost-
savings or small additional annual cost, depending on the country
assessed. However, quality of life information was not incorporat-
ed into this analysis. Thus, treatment decisions favouring either
therapy cannot be based on solid evidence due to the lack of any
cost-utility analysis incorporating quality of life data comparing
combination to ACE inhibitor therapy alone in patients with heart
failure.
Individual trials included only very few patients with heart
failure NYHA IV. Whether combination therapy proves beneficial
in these patients with poor prognosis on standard therapy needs to
be addressed by an adequately powered trial with strict monitoring
of potentially dangerous adverse effects in this particular subgroup
of severely ill patients. Only few patients of included trials had
concomitant treatment with spironolactone, probably due to the
increased risk of hyperkalemia when combining ACE inhibitors,
ARB’s and spironolactone. In the Randomized Aldactone
Evaluation Study (RALES) [37], blockade of aldosterone receptors
by spironolactone, in addition to standard therapy, substantially
reduced the risk of both morbidity and death among patients with
severe heart failure. In the ONTARGET trial combination
therapy reduced proteinuria to a greater extent than monother-
apy, however, overall renal outcomes were worse with combina-
tion therapy [38]. It is well known that blockade of the renin-
angiotensin-aldosterone system results in an initial decline in renal
function but may still prove beneficial in preserving renal function
in the long-term. However, the results of our analysis demonstrate
that the observed decline in renal function associated with
combination therapy is detrimental to patients’ health. Two trials
defined decrease in renal function as either a $50% increase of
serum creatinine from baseline [26,27], and another trial [24] as
one of the following: death from renal failure, end-stage renal
disease requiring chronic dialysis or renal transplantation, or an
increase in serum creatinine concentration leading to temporary
or permanent discontinuation of study medication. In all 3 trials
worsening of renal function occurred more commonly in patients
assigned to combination therapy.
Generally, patients in clinical trials are more strictly monitored
and adverse effects from combination therapy could have been
detected earlier and more appropriately managed than under
‘‘real world’’ conditions. This has been well described for
congestive heart failure patients with hyperkalemia treated with
aldactone [37,39]. Therefore, the higher incidence of adverse
effects associated with combination therapy in randomized
controlled trials may be even higher in clinical practice
questioning the safety of combination therapy even further.
This meta-analysis confirms the findings from the recently
published ONTARGET trial where no reduction in overall
mortality but an increase in potentially serious side effects were
found in patients at high vascular risk or diabetes treated with
combination therapy [40].
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Although we tried to obtain patient level data from primary
investigators in order to conduct time-to-event and subgroup
analyses, our request was not granted by some of the primary
investigators. The lack of individual patient and aggregated follow-
up data collected at uniform time points precluded us from
analysing time-to-event data and from reporting absolute risk
reductions and number needed to treat or to harm. Similarly, we
were not able to identify relevant subgroups which may still benefit
from combination therapy and we were not able to calculate risk
differences that would allow for a better comparison of beneficial
and adverse effects from combination therapy.
Our results have implications for guiding the direction of future
research. There is a need for randomised controlled trials
evaluating the effect of adding ARBs to patients taking ACE
inhibitor therapy and beta-adrenergic antagonists for the treat-
ment of heart failure in order to see whether ARBs offer any
additional benefit to current standard therapy for heart failure.
Alternatively, individual patient data meta-analysis may allow the
identification of subgroups which potentially benefit more from
combination therapy such as younger patients with preserved
renal function ant thus at lower risk to experience worsening renal
function or hyperkalemia.
Conclusions
Combination therapy with ARBs and ACE inhibitors does not
reduce mortality in patients with heart failure when compared to
ACE inhibitor therapy alone. Although combination therapy does
reduce hospitalizations for heart failure, it is associated with more
adverse events and does not reduce all-cause hospitalization. Thus,
based on current evidence, combination therapy with ARBs and
ACE inhibitors may be reserved for patients who remain
symptomatic on therapy with ACE inhibitors under strict
monitoring for any signs of worsening renal function and/or
symptomatic hypotension.
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